Hosted on MSN7h
Omvoh Approved for Crohn's; Fitbit Predicts IBD Flares; H. Pylori and Gastric Cancer
The FDA expanded the approval of mirikizumab (Omvoh) to include treatment of adults with moderately to severely active ...
centerforbiosimilars8h
Biosimilars Drive Cost Savings and Achieve 53% Market Share Across Treatment Areas
Biosimilar launches achieve a 53% market share and a 53% reduction in average drug costs after 5 years of biosimilar ...
Healio12h
IBD drug market rattles as Lilly’s Omvoh nabs FDA approval for second IL-23p19 in Crohn’s
The FDA has approved Omvoh for the treatment of moderately to severely active Crohn’s disease, making it the second ...
centerforbiosimilars16h
Biosimilar Tocilizumab Cost-Effective for Treatment of Rheumatoid Arthritis in Spain
A study from Spain found a subcutaneous tocilizumab biosimilar to be cost-effective when treating patients with rheumatoid ...
The Pharma Letter17h
FDA approves Lilly's Omvoh for Crohn's disease
The US Food and Drug Administration (FDA) has approved Omvoh (mirikizumab-mrkz), from US pharma major Eli Lilly, for the ...